ArticleAntibiotics (Basel, Switzerland)2023
Epidemiological Characteristics and Antimicrobial Resistance Changes of Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Evolution of Antimicrobial Resistance inMicroorganisms · 2026Review
- Development and validation of an interpretable machine learning-based model for predicting carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Carbapenem-resistantFrontiers in medicine · 2026Article
- Antimicrobial Resistance Trends, Resistance Mechanisms, and Antibiotic Consumption in COVID-19 Versus Non-COVID-19 Units: A Seven-Year Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Characteristics of Klebsiella pneumoniae and carbapenem-resistant Klebsiella pneumoniae clinical isolates from COVID-19 patients: a single-center retrospective analysis in a tertiary hospital, China.BMC infectious diseases · 2025Article
- Epidemiological and Antimicrobial Resistance Trends ofInfection and drug resistance · 2025Article
- The Characterisation of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- A scoping review of bacterial resistance among inpatients amidst the COVID-19 pandemic.Journal of global antimicrobial resistance · 2024Article
- The Impact of Infection Control Policies on Hospital Acquired Infections by MDROs from 2016 to 2023.Infection and drug resistance · 2024Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Impact of SARS-CoV-2 Preventive Measures against Healthcare-Associated Infections from Antibiotic-Resistant ESKAPEE Pathogens: A Two-Center, Natural Quasi-Experimental Study in Greece.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the epidemiological characteristics and resistance changes of carbapenem-resistant organisms (CROs) under the COVID-19 outbreak to provide evidence for precise prevention and control measures against hospital-acquired infections during the pandemic.
methodsThe distribution characteristics of CROs (i.e., carbapenem-resistant
resultsThe resistance rate of carbapenem-resistant
conclusionThe COVID-19 pandemic has affected the change in nosocomial infections and resistance rates in CROs, highlighting the need for hospitals to closely monitor CROs, especially in high-risk populations and clinical departments. It is possible that lower adherence to infection control in crowded wards and staffing shortages may have contributed to this trend during the COVID-19 pandemic, which warrants further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.